



Claims

1. A combination product comprising a compound of formula (I):



or a pharmaceutically acceptable salt or co-crystal thereof, and one or more immunotherapeutic agents selected from the group consisting of an anti-CTLA4 antibody, an anti-PD-1 antibody and an anti-PD-L1 antibody.

2. A compound of Formula (I):



or a pharmaceutically acceptable salt or co-crystal thereof; or the combination product according to claim 1 for use in the treatment of cancer.

3. The compound or combination product for use according to claim 2, wherein the cancer is a lung cancer (*e.g.*, a non-small cell lung cancer (NSCLC) (*e.g.*, a NSCLC with squamous and/or non-squamous histology, or a NSCLC adenocarcinoma)), a melanoma (*e.g.*, an advanced melanoma), a renal cancer (*e.g.*, a renal cell carcinoma), a liver cancer, a myeloma (*e.g.*, a multiple myeloma), a prostate cancer, a breast cancer (*e.g.*, a breast cancer that does not express one, two or all of estrogen receptor, progesterone receptor, or Her2/neu, *e.g.*, a triple negative breast cancer), a colorectal cancer, a pancreatic cancer, a head and neck cancer (*e.g.*, head and neck squamous cell carcinoma (HNSCC)), anal cancer, gastro-esophageal cancer, thyroid cancer, cervical cancer, a lymphoproliferative disease (*e.g.*, a post-transplant lymphoproliferative disease) or a hematological cancer, T-cell lymphoma, B-cell lymphoma, a non-Hodgkin lymphoma, or a leukemia (*e.g.*, a myeloid leukemia or a lymphoid leukemia).
4. The compound or combination product for use according to claim 2, wherein the cancer is lung cancer (squamous), lung cancer (adenocarcinoma), head and neck cancer, cervical cancer (squamous), stomach cancer, thyroid cancer, melanoma, nasopharyngeal cancer, or breast cancer.
5. The compound or combination product for use according to claim 2, wherein the cancer is lung cancer or non-small cell lung cancer.
6. The combination product for use according to claim 2, 3, 4 or 5 wherein the immunotherapeutic agent is selected from the group consisting of: ipilimumab, tremelimumab, nivolumab, pembrolizumab, CT-011, AMP-224, MPDL3280A, MEDI4736 and MDX-1105.
7. The combination product for use according to claim 2, 3, 4 or 5 wherein the immunotherapeutic agent is selected from the group consisting of MPDL3280A, MEDI4736 and MDX-1105.

8. The combination product for use according to claim 2, 3, 4 or 5 wherein the immunotherapeutic agent is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab and AMP-224.
9. The combination product for use according to claim 2, 3, 4 or 5 wherein the immunotherapeutic agent is an anti-PD-1 antibody.
10. The combination product for use according to claim 9 wherein the anti PD-1 antibody comprises:
 - (a) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 4, a VHCDR2 amino acid sequence of SEQ ID NO: 5, and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 13, a VLCDR2 amino acid sequence of SEQ ID NO: 14, and a VLCDR3 amino acid sequence of SEQ ID NO: 33;
 - (b) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 1; a VHCDR2 amino acid sequence of SEQ ID NO: 2; and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 10, a VLCDR2 amino acid sequence of SEQ ID NO: 11, and a VLCDR3 amino acid sequence of SEQ ID NO: 32;
 - (c) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 224, a VHCDR2 amino acid sequence of SEQ ID NO: 5, and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 13, a VLCDR2 amino acid sequence of SEQ ID NO: 14, and a VLCDR3 amino acid sequence of SEQ ID NO: 33; or
 - (d) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 224; a VHCDR2 amino acid sequence of SEQ ID NO: 2; and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 10, a VLCDR2 amino acid sequence of SEQ ID NO: 11, and a VLCDR3 amino acid sequence of SEQ ID NO: 32.
11. The combination product for use according to claim 9 or 10, wherein the anti PD-1 antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 38 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 70.
12. The combination product for use according to claim 9, 10 or 11, wherein the anti-PD-1 antibody comprises: a heavy chain comprising the amino acid sequence of SEQ ID NO: 91 and a light chain comprising the amino acid sequence of SEQ ID NO: 72.
13. The combination product for use according to any one of claims 9 to 12, wherein the anti-PD-1 antibody molecule is administered at a dose of about 300 mg once every three weeks, or wherein the anti-PD-1 antibody molecule is administered at a dose of about 400 mg once every four weeks.
14. The combination product for use according to claim 2, 3, 4 or 5, wherein the immunotherapeutic agent is an anti-PD-L1 antibody.
15. The combination product for use according to claim 14, wherein the anti PD-L1 antibody molecule comprises:
 - (a) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 228, a VHCDR2 amino acid sequence of SEQ ID NO: 229, and a VHCDR3 amino acid sequence of SEQ ID NO: 227; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 233, a VLCDR2 amino acid sequence of SEQ ID NO: 234, and a VLCDR3 amino acid sequence of SEQ ID NO: 235;
 - (b) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 225; a VHCDR2 amino acid sequence of SEQ ID NO: 226; and a VHCDR3 amino acid sequence of SEQ ID NO: 227; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 230, a VLCDR2 amino acid sequence of SEQ ID NO: 231, and a VLCDR3 amino acid sequence of SEQ ID NO: 232;
 - (c) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 244, a VHCDR2 amino acid sequence of SEQ ID NO: 229, and a VHCDR3 amino acid sequence of SEQ ID NO: 227; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 233, a VLCDR2 amino acid sequence of SEQ ID NO: 234, and a VLCDR3 amino acid sequence of SEQ ID NO: 235;
 or

- (d) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 244; a VHCDR2 amino acid sequence of SEQ ID NO: 226; and a VHCDR3 amino acid sequence of SEQ ID NO: 227; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 230, a VLCDR2 amino acid sequence of SEQ ID NO: 231, and a VLCDR3 amino acid sequence of SEQ ID NO: 232.
16. The combination product for use according to claim 14 or 15, wherein the anti-PD-L1 antibody molecule comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 236 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 239.
17. The combination product for use according to any one of claims 2-16 wherein the combination of the immunotherapeutic agent is administered together in a single composition or administered separately in two or more different compositions forms; or wherein the immunotherapeutic agent is administered concurrently with, prior to, or subsequent to, the compound of Formula (I).